Dataset opportunity
Celonic — Regulatory Records Dataset Opportunity
Moderate regulatory records dataset held by Celonic, usable for Regulatory RAG and Compliance Copilots.
Score
62
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Partnership (group-level)
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global Regulatory Information Management system market = $2.2 billion in 2024, CAGR 10.9%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📣Press / announcement
Selection by UHC and DZIF for monoclonal antibody process development and GMP manufacturing
source ↗
Profile
Dataset profile
Type
Regulatory Records Dataset
Modality
Text
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Mixed ownership — licensing rights to clarify
Buyer persona
RegTech & compliance-AI vendors
Celonic holds a comprehensive Regulatory Records Dataset in Text modality, comprising business_records, industrial_data, and regulatory filings. This structured and domain-specific data provides the essential evidence needed to train and ground a Regulatory RAG system, enabling it to accurately interpret and respond to complex queries on biopharmaceutical manufacturing and compliance.
The business value is clear within the global Regulatory Information Management system market, which was valued at $2.2 billion in 2024 and is projected to grow at a 10.9% CAGR. [4] While access requires navigating complexities such as split data ownership between client and proprietary data, a strict GMP environment, and client confidentiality agreements, this curated dataset is exceptionally valuable. It offers a rare and defensible asset for an AI buyer to master regulatory compliance, making the negotiation for access a worthwhile strategic investment. ⚠ Diligence (valuable data, access to negotiate): Data ownership is split between client-specific molecule data and Celonic's proprietary process/platform data.; Strict GMP (Good Manufacturing Practice) regulatory environment governs data integrity and access.; Confidentiality agreements with biotech/pharma clients limit the sharing of specific production runs. · corporate: subsidiary of J. Rettenmaier & Söhne (JRS Group).
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Celonic holds a rare, end-to-end dataset detailing the proprietary manufacturing, quality control, and performance of next-generation biologics and ATMPs. This is a critical asset for RegTech and compliance-AI vendors seeking to build sophisticated Regulatory RAG systems that can navigate complex submissions. In a global regulatory information management market worth over $2.2 billion, this real-world evidence provides a significant competitive advantage for training models on proprietary processes and outcomes that are otherwise inaccessible.
See dimension details ↓- Dataset Specificity78
dominant 'regulatory', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Regulatory RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
AI buyer demand is high, driven by the need to automate compliance in the rapidly growing Regulatory Information Management system market, which is expanding at a 10.9% CAGR. [4]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility28
restricted/unknown
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, subsidiary of J. Rettenmaier & Söhne (JRS Group)
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License36
ownership=mixed, licensing=rights_unclear
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence50
subsidiary of J. Rettenmaier & Söhne (JRS Group)
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ good target — Celonic is a biologics CDMO whose core business is contract manufacturing and development services; it generates valuable regulatory and process data as a by-product, making it a strong potential data holder. Issues: The primary issue is data ownership: the regulatory and process data generated during client projects is likely owned by the respective clients, not by Celonic.; The company is a subsidiary of the private J. Rettenmaier & Söhne (JRS Group), which could add complexity to negotiations. [6, 8, 14]
- Deep Qualification85
⚠ needs review — Celonic is a classic data_holder; as a CDMO, it generates vast amounts of regulatory and manufacturing data as a byproduct of its core service. However, this data is subject to mixed ownership and stringent client confidentiality agreements, making direct resale highly restricted. [licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
This evidence consists of time-series data from GMP manufacturing processes for biologics, which is crucial for AI models that predict production outcomes and validate process consistency for regulatory filings.
business_records
This evidence confirms ownership of performance records for the proprietary CHOvolution® cell line, a unique dataset for training AI on the nuances of a specific, high-performance expression platform.
Regulatory records
This text-based evidence comprises extensive quality control and analytical datasets for ATMPs, providing an invaluable corpus for training regulatory AI to handle the complex documentation required for advanced therapies.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Celonic Regulatory Records — a Moderate regulatory records dataset (Text modality) in the healthcare domain. Primary AI use-case: Regulatory RAG. Market signal: Global Regulatory Information Management system market = $2.2 billion in 2024, CAGR 10.9% (source: Global Market Insights). [4]. Investment score 62.0/100 (confidence 0.49). Recommended action: Partnership (group-level).
From the marketplace
Explore live data opportunities
Zetasurgical — Image Dataset Opportunity
View opportunity →healthcareMicrosure — Sensor Telemetry Dataset Opportunity
View opportunity →mobilityMt Logistik — Regulatory Records Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- Why Buy External Data?3 min read
- Buying Data Without Mistakes3 min read
- Your Expertise is Gold for AI3 min read